JP2022530443A5 - - Google Patents

Info

Publication number
JP2022530443A5
JP2022530443A5 JP2021563172A JP2021563172A JP2022530443A5 JP 2022530443 A5 JP2022530443 A5 JP 2022530443A5 JP 2021563172 A JP2021563172 A JP 2021563172A JP 2021563172 A JP2021563172 A JP 2021563172A JP 2022530443 A5 JP2022530443 A5 JP 2022530443A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
antigen
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021563172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530443A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029664 external-priority patent/WO2020219778A2/en
Publication of JP2022530443A publication Critical patent/JP2022530443A/ja
Publication of JP2022530443A5 publication Critical patent/JP2022530443A5/ja
Withdrawn legal-status Critical Current

Links

JP2021563172A 2019-04-24 2020-04-23 抗cd117抗体薬物複合体およびその使用 Withdrawn JP2022530443A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838286P 2019-04-24 2019-04-24
US62/838,286 2019-04-24
PCT/US2020/029664 WO2020219778A2 (en) 2019-04-24 2020-04-23 Anti-cd117 antibody-drug conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2022530443A JP2022530443A (ja) 2022-06-29
JP2022530443A5 true JP2022530443A5 (cg-RX-API-DMAC10.html) 2022-08-23

Family

ID=72940692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563172A Withdrawn JP2022530443A (ja) 2019-04-24 2020-04-23 抗cd117抗体薬物複合体およびその使用

Country Status (4)

Country Link
US (1) US20220177577A1 (cg-RX-API-DMAC10.html)
EP (1) EP3958899A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022530443A (cg-RX-API-DMAC10.html)
WO (1) WO2020219778A2 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
EP3958878A4 (en) * 2019-04-24 2022-12-28 Magenta Therapeutics, Inc. CONDITIONING METHODS FOR GENE THERAPY
JP2022530442A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド アントラサイクリン抗体薬物複合体およびその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2613841T3 (es) * 2008-07-16 2017-05-26 Medical And Biological Laboratories Co., Ltd. Anticuerpo anti-CLCP1 humano y uso del mismo
EP4063391A1 (en) * 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
PT3370768T (pt) * 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
US10111966B2 (en) * 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
EP3700568A4 (en) * 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
US10882915B2 (en) * 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
JP2021526525A (ja) * 2018-06-07 2021-10-07 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 抗体薬物コンジュゲート(adcs)を用いた治療方法
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
AU2019374055B2 (en) * 2018-10-30 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods for allogeneic hematopoietic stem cell transplantation

Similar Documents

Publication Publication Date Title
JP7650819B2 (ja) 抗-cd45抗体薬物コンジュゲート及びその使用
US20260078148A1 (en) Amatoxin antibody-drug conjugates and uses thereof
JP7709376B2 (ja) Fcサイレンス化抗体薬物コンジュゲート(ADC)及びその使用
JP7669269B2 (ja) 抗-cd45抗体及びそのコンジュゲート
JP7280254B2 (ja) Cd117+細胞を減少させるための組成物及び方法
TWI904109B (zh) 抗cd45抗體及其結合物
US20220175944A1 (en) Anti-cd117 antibody-drug conjugates and uses thereof
JP2021500375A5 (cg-RX-API-DMAC10.html)
JP2021504412A (ja) Cd5+細胞の枯渇のための組成物および方法
JP2022529726A5 (cg-RX-API-DMAC10.html)
US20220177577A1 (en) Anti-cd117 antibody drug conjugates and uses thereof
US20200376135A1 (en) Fc silenced antibody drug conjugates (adcs) and uses thereof
US20220226493A1 (en) Anthracycline antibody-drug conjugates and uses thereof
JP2022529726A (ja) Anti-cd117とその使用
JP2025172753A (ja) 自己免疫疾患を治療するための方法および組成物
JP2022529727A5 (cg-RX-API-DMAC10.html)
JP2022529727A (ja) Anti-cd117 とその使用
JP2021517133A (ja) 抗cd252抗体、コンジュゲート、および使用方法